ebook Munafa Stock Market Course + Intraday & FNO calls  

       

RDY announcements Dr. Reddy's Laboratories Ltd announcements and dividends declared USA

Dr. Reddy's Laboratories Ltd Complete list of announcements declared & dividend announcements by Dr. Reddy's Laboratories Ltd RDY

Dr. Reddy's Laboratories Ltd RDY listed on USA and deals in Health Care Major Pharmaceuticals

Announcements and dividends declared by Dr. Reddy's Laboratories Ltd RDY

Dr Reddy's Laboratories Q4 Results: Cons PAT falls 86% YoY to Rs 221 crore, revenue dips 12%; Rs 8 per share dividend announced
Dr Reddy's Laboratories Q4 Results: Dr. Reddy's Laboratories reported a consolidated net profit at Rs 221 crore in the March-ended quarter versus Rs 1,587 crore in the year ago period, an 86% YoY fall.
Announcement as on 12 May 2026

Dr Reddy's and Nestle Health Science strengthen presence in diabetes, obesity nutrition space
Dr Reddy's teams up with Nestle Health Science to introduce Celevida GLP+, a specialized supplement crafted for those navigating the challenges of GLP-1/GIP therapy for type 2 diabetes and obesity.
Announcement as on 07 May 2026

Dr Reddy's gets Health Canada nod for generic semaglutide injection
Dr Reddy's Laboratories has secured market authorization from Health Canada for its generic semaglutide injection. This marks a significant achievement as the first company to receive approval for this diabetes treatment in Canada. The company is now prepa
Announcement as on 29 April 2026

Dr Reddy’s shares fall 2% after Goldman Sachs downgrades, Citi turns cautious
Dr Reddy’s shares fell after Goldman Sachs and Citigroup turned cautious, citing limited growth visibility, pipeline concerns and valuation risks. Brokerages flagged lower earnings potential amid generics pricing pressure and muted opportunities in semaglu
Announcement as on 24 April 2026

Dr Reddy's gets nod to roll out generic oral semaglutide drug
"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to Novo Nordisk's oral semaglutide (Rybelsus brand). Based on this clinical evidence, our product has received regulator
Announcement as on 16 April 2026

Announcements by Dr. Reddy's Laboratories Ltd first page | Next page |

RDY Dr. Reddy's Laboratories Ltd current price & indicator signals

Moving Averages for Dr. Reddy's Laboratories Ltd

  • 5Day Average: 13.14
  • 12Day Average: 13.3
  • 20Day Average: 13.39
  • 50Day Average: 13.55
  • 100Day Average: 13.74
  • 150Day Average: 13.82
  • 200Day Average: 13.93

RDY Indicators & signals

Indicator MACD (12,26,9)

13.31, 13.38, -0.09
Indicator MACD is in negative zone

Indicator ADX (14)

8.33, 32.5, 27.5
Indicator ADX is indicating that momentum is weak.
Indicator ADX is showing that momentum is towards buying

Indicator RSI (14)

Current RSI is: 52
Indicator RSI is indicating buying momentum and stock might rise.

Recent prices of RDY Dr. Reddy's Laboratories Ltd are as follows: Daily volume is divided by 10 day averaged volume

Date Close Range Change % Volume
15 Fri May 2026 13.61 13.58 to 13.90 0.89% 0.59 times
14 Thu May 2026 13.49 13.28 to 13.65 3.85% 0.86 times
13 Wed May 2026 12.99 12.74 to 13.00 4.25% 1.73 times
12 Tue May 2026 12.46 12.19 to 12.74 -5.18% 1.63 times
11 Mon May 2026 13.14 13.11 to 13.29 -0.68% 0.88 times
08 Fri May 2026 13.23 13.22 to 13.56 -1.49% 0.66 times
07 Thu May 2026 13.43 13.43 to 13.65 -0.22% 0.82 times
06 Wed May 2026 13.46 13.40 to 13.72 0% 1.14 times
06 Wed May 2026 13.46 13.40 to 13.72 1.51% 1.14 times
05 Tue May 2026 13.26 13.21 to 13.39 -0.67% 0.48 times
04 Mon May 2026 13.35 13.27 to 13.55 -2.7% 0.66 times
01 Fri May 2026 13.72 13.64 to 13.81 0.59% 0.56 times

Videos related to: RDY announcements Dr. Reddy's Laboratories Ltd announcements and dividends declared USA

Hindi Video Most Important Stock Market Video. No Success Without This Formula

Hindi Video What Is Needed To Succeed In Stock Markets

RDY announcements Dr. Reddy's Laboratories Ltd announcements and dividends declared USA

 

Back to top